BRT Labs

BRT Labs is a long-established, privately-held preclinical CRO focused exclusively on immunology and immune safety testing. The company leverages over 100 years of combined scientific staff experience to offer tailored, regulatory-standard studies, including specialized host resistance models and humanized mouse systems, primarily serving pharmaceutical, biotech, and chemical manufacturing clients. With a strong reputation built over 25+ years, BRT operates as a niche service provider in the preclinical research ecosystem, supporting drug development from early discovery through regulatory submission. Its business model is entirely service-based, generating revenue from contracted research studies.

A suite of preclinical immunology models and assays, including specialized host resistance infection models (bacterial, viral, fungal), humanized mouse systems, in vitro immunotoxicology and immunopharmacology assays, and hypersensitivity testing platforms. This integrated service platform is used to assess immune safety, efficacy, and immunotoxicity for client compounds.

BRT competes in the fragmented preclinical CRO market, differentiated by its narrow focus on immunology. It faces competition from large, diversified CROs (e.g., Charles River, Labcorp) that offer immunotoxicology as part of broad packages, as well as from other niche immunology-focused laboratories. Its competitive edge lies in its deep expertise, long-standing reputation, and specialized model systems like its host resistance portfolio.